Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were up as much as 8.2% on Thursday morning after the biotech company announced positive news on Thursday for a phase 3 trial for Dupixent (dupilumab) to treat patients with chronic obstructive pulmonary disease (COPD). Regeneron's shares are up more than 18% this year, and the stock has a 52-week low of $538.01 and a 52-week high of $812.69. Regeneron partnered with Sanofi (NASDAQ: SNY) on the phase 3 trial and said it met all primary and secondary endpoints compared to a placebo on patients with uncontrolled COPD and evidence of type 2 inflammation.